echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > NEJM: Efficacy of Ranilanol in the treatment of NASH

    NEJM: Efficacy of Ranilanol in the treatment of NASH

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The treatment of non-alcoholic steatohepatitis (NASH) has not yet met clinical needs
    .
    Lanilano is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that regulates key metabolic, inflammatory and fibrotic pathways in the pathogenesis of NASH


    .


    Recently, a research article was published in the top medical journal NEJM.
    In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with non-cirrhotic and highly active NASH were randomly assigned to receive a 1:1:1 ratio.
    1200mg or 800mg ranilanol or placebo, once a day for 24 weeks
    .

    The primary endpoint of the study is the SAF-A score (the active part of the scoring system for steatosis, mobility, and fibrosis [SAF], including the swelling and inflammation scores) decreased by at least 2 points, but the fibrosis did not worsen; SAF-A score range From 0 to 4, the higher the score, the more severe the disease activity
    .
    Secondary endpoints include resolution of NASH and fibrosis


    .


    A total of 247 patients in the study were randomized, of which 103 (42%) patients had type 2 diabetes , and 188 (76%) patients had significant (moderate) or advanced fibrosis
    .
    Compared with patients who received placebo, the percentage of patients whose SAF-A score decreased by at least 2 points and did not worsen fibrosis was significantly higher in patients who received 1200 mg, but it was higher in patients who received 800 mg of La Nilanol Otherwise (1200mg vs.


    placebo, 55% vs.


    diabetes

    In this phase 2b trial involving patients with active NASH, the percentage of patients whose SAF-A score decreased by at least 2 points and who did not experience fibrosis deterioration was significantly higher than that of placebo
    .
    These results support the further evaluation of Ranilanno's effect in a phase 3 trial


    .


    In this phase 2b trial involving patients with active NASH, the percentage of patients whose SAF-A score decreased by at least 2 points and who did not experience fibrosis deterioration was significantly higher than that of placebo



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.